Study explores nasal spray flu vaccine effects in children

The Evolution of Pediatric Immunization: Moving Beyond the Needle

For many children, the annual flu shot is less about health and more about the fear of the needle. This psychological barrier, known as needle phobia, often leads to distress for both the child and the parent, sometimes resulting in delayed or skipped vaccinations. However, a shift toward needle-free alternatives is beginning to reshape the landscape of pediatric healthcare.

The introduction of nasal spray vaccines, such as FluMist manufactured by AstraZeneca, represents a pivotal change in how we approach childhood immunity. By replacing the traditional injection with a simple spray, healthcare providers are addressing the emotional hurdles that often hinder vaccine uptake.

Breaking the Barrier of Vaccine Hesitancy

Vaccine hesitancy isn’t always about the science; often, it is about the experience. Recent data from the 2025 National Vaccination Insights project highlights a significant trend: 72.2 per cent of parents agreed that a needle-free option would make them more likely to prioritize vaccinations for their children.

This suggests that the “fear factor” is a primary driver of low immunization rates. In Victoria, for example, vaccination rates in 2024 were notably low, with only 32 per cent of children aged six months to five years and just 15 per cent of those aged five to 15 receiving their shots.

As Danica, a parent of a child participating in current research, notes: “A lot of young children are needle phobic… For those children this nasal spray is going to be a game-changer.” This sentiment underscores a future where the delivery method of a vaccine is just as important as the medicine itself in ensuring public health compliance.

Precision Medicine: Tailoring Vaccines for the Southern Hemisphere

One of the most significant future trends in immunology is the move toward regional customization. Historically, much of the global flu monitoring and strain selection has focused on populations in the Northern Hemisphere. This can leave gaps in effectiveness for those living elsewhere.

The SNIFFLES study, led by the Murdoch Children’s Research Institute (MCRI), is tackling this head-on. By providing blood samples from Australian children to the World Health Organization (WHO), researchers are helping to fill a critical data gap.

Associate Professor Shidan Tosif, Project Lead at MCRI and a pediatrician at The Royal Children’s Hospital, explains that these samples ensure “our children’s immune responses are considered when flu vaccine strains are chosen.” This shift toward Southern Hemisphere-specific data is expected to improve vaccine effectiveness and bolster global influenza preparedness.

The Future of Immune Response Research

The goal of current research is not just to make vaccination “easier,” but to understand the biological differences in how the body responds to different delivery methods. By comparing the nasal spray vaccine with the standard injectable shot, scientists can better understand the immune response in children aged two to nine.

This data is being analyzed by high-authority bodies, including the MOVE Consortium in the UK and the WHO Collaborating Centre for Reference and Research on Influenza at The Doherty Institute. The insights gained will likely lead to more personalized vaccination schedules and potentially more potent vaccines tailored to specific age groups.

For more information on pediatric health trends, you can explore the Murdoch Children’s Research Institute or check our other guides on modern immunization practices.

Frequently Asked Questions

What is FluMist?
FluMist is a nasal spray flu vaccine manufactured by AstraZeneca. It is approved by the Therapeutic Goods Administration (TGA) for safe and effective use in children aged two to 17 years.

Why is the SNIFFLES study important?
The study helps the WHO formulate flu vaccines and select strains specifically for children in the Southern Hemisphere, ensuring better regional protection.

Can parents choose between the spray and the shot?
Yes, in the context of the SNIFFLES study, parents can choose which vaccine option they prefer their children to receive.

Who is leading the research on nasal spray vaccines in Australia?
The research is led by Associate Professor Shidan Tosif and the Murdoch Children’s Research Institute (MCRI).